

Ricardo Andres Angel Villadiego

Director: Maria Francisca Villegas Torres

Codirector: Jaime David Vega Paez

Trabajo de grado

Microbiología


ABSTRACT

Galantamine is an alkaloid used in the treatment of Alzheimer's disease. However, its current method of production requires extraction from plants from *Amaryllidaceae* family, leading to low yields for industrial standards. Its biosynthesis is complex and not fully known, but there are identified pathways to one of its precursors 4'-O-methylnorbelladine. *Saccharomyces cerevisiae* can be a suitable cell host for the heterologous production of 4'-O-methylnorbelladine for its standard usage and tolerance to industrial conditions. In this work, 18 previously identified alternative pathways for 4'-O-methylnorbelladine and the native pathway were assessed against a decision matrix which took into account 4 criteria: metabolic risk, pathway knowledge risk, enzymatic risk and additional requirements risk. The best pathways with the minimum risk score were selected for optimization along with the native pathway for comparison. The Optknock algorithm was used to identify possible knockouts of reaction that would lead to an increased production of 4'-O-methylnorbelladine. The results showed that alternative pathways can provide a better yield of the target metabolite while also having a lesser associated risk in the decision matrix than the native pathway.



INTRODUCTION

- The alkaloid galantamine is an inhibitor of acetylcholinesterase, an enzyme that breaks down the neurotransmitter acetylcholine[1]. For this reason, galantamine is used as a treatment for Alzheimer's disease[2]. It is naturally produced by members of the *Amaryllidaceae* family[3].
- Its organic synthesis has been a challenge due its chemical complexity, limiting its production to solely plants. As a consequence, crop competition and naturally low production of galantamine in these plants have resulted in yields that are considered low for industrial standards[4].
- The metabolic pathway leading to the biosynthesis of galantamine is not fully known. According to the current literature[5], There is an established pathway leading to 4'-O-methylnorbelladine.
- *S. cerevisiae* is an Eukaryotic model organism that has been extensively researched and is widely used in industrial applications for their tolerance to industrial conditions[6] and it's proven to be a viable host for a cell factory to produce heterologous proteins[7].
- 4'-O-methylnorbelladine can be produced from reactions that derive from the central metabolism of *S. cerevisiae*. Being able to produce this compound in an heterologous microorganism could be a first step to the large-scale synthesis of galantamine.

METHODS



18 PATHWAY CANDIDATES + NATIVE PATHWAY



RESULTS




Figure 1. A) 4'-O-methylnorbelladine flux by biomass flux of pathways 01_1, 07_1 and NAT with 2 deletions constraint. **B)** Frequency of most knocked reactions in pathway 01_1 with 2 deletions and greater than 20 flux constraint. **C)** Frequency of most knocked reactions in pathway 07_1 with 2 deletions and greater than 20 flux constraint. **D)** Frequency of most knocked reactions in pathway NAT with 2 deletions and greater than 20 flux constraint. **E)** 4'-O-methylnorbelladine flux by biomass flux of pathways 01_1, 07_1 and NAT with 1 deletion constraint. **F)** 4'-O-methylnorbelladine flux by biomass flux of pathways 01_1, 07_1 and NAT with 3 deletions constraint.

CONCLUSIONS

- Different pathways present a different biomass/target tradeoff.
- Knockout optimization is dependent on pathway. Some can present more different solutions than others given the same set of constraints. The abundance of knocked reactions vary between pathways.
- Alternative pathways can provide a better yield of 4'-O-methylnorbelladine.
- Alternative pathways can have less risk associated with its construction.
- It is worth to search for alternative pathways as they can provide more viable implementations.

REFERENCES

1. Taylor, P., Camp, S., & Radić, Z. (2009). Acetylcholinesterase. In *Encyclopedia of Neuroscience* (pp. 5–7). Elsevier. <https://doi.org/10.1016/b978-008045046-9.01132-3>
2. Olin, J., & Schneider, L. (2002). Galantamine for dementia due to Alzheimer's disease. In *The Cochrane Database of Systematic Reviews*. John Wiley & Sons, Ltd. <https://doi.org/10.1002/14651858.cd001747>
3. National Center for Biotechnology Information (2023). PubChem Compound Summary for CID 9651, Galantamine. Retrieved May 31, 2023 from <https://pubchem.ncbi.nlm.nih.gov/compound/Galantamine>.
4. Santos, G. S., Sinoti, S. B. P., de Almeida, F. T. C., Silveira, D., Simeoni, L. A., & Gomes-Copeland, K. K. P. (2020). Use of galantamine in the treatment of Alzheimer's disease and strategies to optimize its biosynthesis using the in vitro culture technique. In *Plant Cell, Tissue and Organ Culture (PCTOC)* (Vol. 143, Issue 1, pp. 13–29). Springer Science and Business Media LLC. <https://doi.org/10.1007/s11240-020-01911-5>
5. Desgagné-Penix, I. (2020). Biosynthesis of alkaloids in Amaryllidaceae plants: a review. In *Phytochemistry Reviews* (Vol. 20, Issue 2, pp. 409–431). Springer Science and Business Media LLC. <https://doi.org/10.1007/s11101-020-09678-5>
6. Hong, K.-K., & Nielsen, J. (2012). Metabolic engineering of *Saccharomyces cerevisiae*: a key cell factory platform for future biorefineries. In *Cellular and Molecular Life Sciences* (Vol. 69, Issue 16, pp. 2671–2690). Springer Science and Business Media LLC. <https://doi.org/10.1007/s00018-012-0945-1>
7. Kavšček, M., Stražar, M., Turk, T., Natter, K., & Petrovič, U. (2015). Yeast as a cell factory: current state and perspectives. In *Microbial Cell Factories* (Vol. 14, Issue 1). Springer Science and Business Media LLC. <https://doi.org/10.1186/s12934-015-0281-x>